SCHEMBL6403087

SCHEMBL6403087

CC(C[CH]C(=O)N[C@H]1CCCN(Cc2ccc3ccccc3n2)CC1=O)C(N)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.41
MCHR1 Q99705 2/20 0.41
OPRL1 P41146 1/20 0.39
FAAH O00519 3/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
PDE2A O00408 1/20 0.38
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5092918 0.86 KMT2A (0.43) PDE2A
SCHEMBL4687324 0.84 ALDH1A1 (0.41) CTSLCTSSCTSK
SCHEMBL6403094 0.82 CTSK (0.48) PTPN1MCHR1OPRL1FAAHCTSL
SCHEMBL5096735 0.81 KMT2A (0.43)
SCHEMBL5096703 0.79 ALDH1A1 (0.41) MCHR1CYP3A4
SCHEMBL5105413 0.78 HSD11B1 (0.35) CTSLCTSSCTSK
SCHEMBL5099657 0.78 LMNA (0.39)
SCHEMBL5099248 0.77 KMT2A (0.45) PDE2A
SCHEMBL5099688 0.77 ACHE (0.34) CTSK
SCHEMBL5099710 0.77 DNM1L (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050256104-A1 substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation SMITHKLINE BEECHAM CORPORATION 2005-11-17 US disclosed
US-20030225061-A1 Protease inhibitors MARQUIS ROBERT WELLS (US) 2003-12-04 US disclosed
US-20030044399-A1 Method of treatment SMITHKLINE BEECHAM CORPORATION 2003-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225061-A1 Protease inhibitors CTSK, MMP13, CTSZ PTPN1 2363/4885MCHR1 4794/4885OPRL1 3802/4885
US-20030044399-A1 Method of treatment DNPEP, PEPD, ANPEP PTPN1 2752/4885MCHR1 1682/4885OPRL1 3598/4885
US-20050256104-A1 substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation CTSK, CTSZ, CTSE PTPN1 1482/4885MCHR1 4800/4885OPRL1 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.